Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial
about
sameAs
Adenosine-diphosphate (ADP) receptor antagonists for the prevention of cardiovascular disease in type 2 diabetes mellitusAspirin and extended-release dipyridamole versus clopidogrel for recurrent strokeLong-Term Antiplatelet Mono- and Dual Therapies After Ischemic Stroke or Transient Ischemic Attack: Network Meta-AnalysisAntiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysisAggrenox((R)) versus other pharmacotherapy in preventing recurrent strokePreventable stroke and stroke preventionReview of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agentsSecondary prevention of stroke and transient ischemic attack: is more platelet inhibition the answer?Measurable prediction for the single patient and the results of large double blind controlled randomized trialsTiclopidine-, clopidogrel-, and prasugrel-associated thrombotic thrombocytopenic purpura: a 20-year review from the Southern Network on Adverse Reactions (SONAR).Effect of sex on outcome after recurrent stroke in African Americans: results from the African American Antiplatelet Stroke Prevention Study.Guidelines on the use of therapeutic apheresis in clinical practice--evidence-based approach from the Apheresis Applications Committee of the American Society for Apheresis.Enrollment of women and minorities in NINDS trialsAntiplatelets in secondary stroke preventionAntiplatelet therapy in secondary stroke prevention--state of the artPrevention and Management of Cerebral Small Vessel DiseaseBleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies.Update on stroke prevention.Clopidogrel versus Other Antiplatelet Agents in the Secondary Prevention of Vascular Events in Adults with Cerebrovascular Disease: Clinical and Cost-Effectiveness Analyses.Platelet P2 receptors: old and new targets for antithrombotic drugs.Secondary prevention of atherothrombotic events after ischemic stroke.The role of antiplatelet therapy in the management of ischemic stroke: implementation of guidelines in current practice.Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?Pharmacogenetics and stroke.Antithrombotic medication for stroke prevention.A critical review of aspirin in the secondary prevention of noncardioembolic ischaemic stroke.The influence of study characteristics on reporting of subgroup analyses in randomised controlled trials: systematic review.Advancements in understanding the mechanisms of symptomatic lacunar ischemic stroke: translation of knowledge to prevention strategies.P2Y12 receptor inhibitors for secondary prevention of ischemic stroke.When a Single Antiplatelet Agent for Stroke Prevention Is Not Enough: Current Evidence and Future Applications of Dual Antiplatelet Therapy.Antiplatelet and Anticoagulant Therapies for Prevention of Ischemic Stroke.Discovery, development and effectiveness of coagulation-inhibiting drugs for stroke therapy.Comparative Efficacy and Safety of Nine Anti-Platelet Therapies for Patients with Ischemic Stroke or Transient Ischemic Attack: a Mixed Treatment Comparisons.Race, ethnic group, and clinical research.Stroke: secondary prevention.Aspirin plus dipyridamole has the highest surface under the cumulative ranking curves (SUCRA) values in terms of mortality, intracranial hemorrhage, and adverse event rate among 7 drug therapies in the treatment of cerebral infarction.
P2860
Q24203035-549669AA-D183-40EB-ADED-D705207F6CF0Q24646522-9516DDC4-D30C-4B70-8670-DC75F5F08658Q26797510-FF936BA9-59EC-4FED-9068-E330EEA7FB8FQ28076042-BFAC6FE1-777B-4F6E-88AA-35CFAD76FB53Q28166526-9FFC1654-4390-4053-BBE1-F5C2D6FB554DQ28187602-23DC8B40-8C47-4A8B-8AC9-5C5A0F925B6FQ28192470-830248B4-F530-4015-8D5D-5A04D1043C47Q28221595-6298FA9B-DB7F-4F39-A17E-EEB8BFAC36ABQ33326637-643B9CFB-2C8E-42A9-B307-76F8707CD6C2Q33404125-08624544-DB1A-482D-B934-26F9CB07B211Q33976391-C6EE9BEE-9826-4A72-82C2-C8587C8177C5Q34122035-F0A47F3E-4DFF-4C66-9297-8FF7D2B956A8Q34555467-59751FC3-C47C-4A80-A382-DA39B04BF522Q35091647-5423EB4F-C9BF-46B6-9A1A-0A983BA7671AQ35216412-FDBACD9E-6662-414F-BCBA-447E7361F1F4Q35698425-FA586C50-CE8C-41B5-9FD5-1D97A7D970A1Q36094923-D1D66B6B-ACD2-4C5B-8CDD-866C994303E8Q36131773-2024CEF3-7438-4390-9CC4-7D6E4CECB7A2Q36137786-959024DE-E5B1-4D2B-B5A3-ECDF0DBD76D5Q36691632-028EB20B-D91B-4FE6-BC7B-2BB3EF80421FQ37148345-152268BB-D61F-4112-8330-6A2F49AC41ECQ37204401-C1644F69-1498-4DD6-9D91-3DC8D93520F3Q37362773-68C94367-96A7-4C45-A98F-A37A660C9F66Q37425335-CCAF9A18-0A5B-4000-8397-886F59464EF5Q37611046-7AA1BA17-095A-4F77-83B8-F41A3B9CA502Q37773416-EF5C18BD-CE9E-44E1-8FEC-89833459A9A9Q37858846-7E180BB4-5EAB-4DA1-A2BD-A65196B70B3DQ38184638-C685921B-D0DE-4184-839F-501314C34839Q38420789-F451E15B-CBB9-40E2-B155-1509E18D2E32Q38904060-5A2CAF2A-6BD1-47E3-9C4A-8367218FA36FQ38909618-1BF431E0-C8E9-4E73-8B73-0E81978B2553Q39766399-34792985-CB6D-4F10-BC37-EEDD902B81DEQ40023249-4FDD9334-F7CF-45EC-B716-1CBE53F47796Q42967776-45DC5723-E787-445F-BC72-DEE32CA3ECB9Q46722175-6D86829B-777F-4FCB-882E-8CF051F0EC76Q55003714-1B858096-FCD5-45A7-AD34-8321C97BFDF9
P2860
Aspirin and ticlopidine for prevention of recurrent stroke in black patients: a randomized trial
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Aspirin and ticlopidine for pr ...... k patients: a randomized trial
@ast
Aspirin and ticlopidine for pr ...... k patients: a randomized trial
@en
Aspirin and ticlopidine for pr ...... k patients: a randomized trial
@nl
type
label
Aspirin and ticlopidine for pr ...... k patients: a randomized trial
@ast
Aspirin and ticlopidine for pr ...... k patients: a randomized trial
@en
Aspirin and ticlopidine for pr ...... k patients: a randomized trial
@nl
prefLabel
Aspirin and ticlopidine for pr ...... k patients: a randomized trial
@ast
Aspirin and ticlopidine for pr ...... k patients: a randomized trial
@en
Aspirin and ticlopidine for pr ...... k patients: a randomized trial
@nl
P2093
P3181
P356
P1476
Aspirin and ticlopidine for pr ...... k patients: a randomized trial
@en
P2093
DeJuran Richardson
Elena Hung
Michael Kelly
Philip B Gorelick
Sean Ruland
Steven Kittner
Yvonne Harris
P304
P3181
P356
10.1001/JAMA.289.22.2947
P407
P50
P577
2003-06-11T00:00:00Z